Category: Peptides Research
Research articles and educational content on peptides and longevity compounds, authored and reviewed by Dr. James, a board-certified neurosurgeon trained at Yale University, and Dr. Tom, a licensed pharmacist. All content is for research and educational purposes only.
-
TB-500 (Thymosin Beta-4): Mechanism of Action, Human Clinical Trials, and Research Applications
A scientific review of TB-500 (Thymosin Beta-4) — mechanism of action via actin regulation, human clinical trial data, WADA status, and research applications.
-
BPC-157 Mechanism of Action: Scientific Studies, Animal Research, and the FAK-Paxillin Pathway
A comprehensive review of BPC-157 mechanism of action across scientific studies — covering the FAK-paxillin pathway, angiogenesis, neuroprotection, and animal model data.
-
NAD+ vs NMN: What Research Reveals About These Two Longevity Compounds
Research and educational content authored by Dr. James Nguyen, board-certified neurosurgeon and scientific advisor to BLL Peptides. For research and educational purposes only. Not for human or animal use. As research into cellular aging and metabolic function has expanded, two compounds have attracted sustained scientific attention: NAD+ (nicotinamide adenine dinucleotide) and NMN (nicotinamide mononucleotide). Though…
-
BPC-157 vs TB-500: Comparing Two Research Peptides for Tissue Repair and Recovery
Research and educational content authored by Dr. James Nguyen, board-certified neurosurgeon and scientific advisor to BLL Peptides. For research and educational purposes only. Not for human or animal use. BPC-157 and TB-500 are among the most studied peptides in regenerative biology research. Both have accumulated substantial preclinical literature examining tissue repair, but their mechanisms are…
-
Tirzepatide vs Semaglutide: A Research Comparison of Dual GIP/GLP-1 vs Selective GLP-1 Mechanisms
Research and educational content authored by Dr. James Nguyen, board-certified neurosurgeon and scientific advisor to BLL Peptides. For research and educational purposes only. Not for human or animal use. Among the most closely studied peptide compounds in contemporary metabolic research, tirzepatide and semaglutide stand out for their effects on incretin receptor pathways. Yet these two…
-
PT-141 (Bremelanotide): What a Neurosurgeon Finds Fascinating About This Melanocortin Peptide
Every now and then, a compound stops me mid-chart review and demands my full attention. PT-141 was one of those moments — and I wasn’t even looking for it. I was consulting on a spinal cord injury case, examining whether supraspinal pathways might still mediate certain physiological responses when peripheral nerve signaling is disrupted. The…
-
NAD+ Research: What a Neurosurgeon Found in the Cellular Energy and Brain Aging Literature
Halfway through a twelve-hour craniotomy a few years back, I found myself thinking about something that had nothing to do with the surgical field in front of me. I was thinking about what, exactly, was keeping this patient’s brain alive. Not the anesthesia, not the monitors — the underlying cellular machinery. The mitochondria cycling through…
-
Semax Peptide Research: A Neurosurgeon’s Honest Look at the BDNF Data
I was skeptical when a colleague first slid a paper on Semax across the conference table. A synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone, developed in the Soviet Union in the 1980s, with a clinical history primarily documented in Russian-language literature — that’s not the kind of origin story that commands instant credibility…
-
The Peptide That Drops 60% by Age 60: My Deep Dive Into GHK-Cu Research
There’s a peptide circulating in your bloodstream right now that peaks in your 20s and falls by roughly 60% by the time you reach 60. When I first came across that statistic in a pharmacology review, I stopped and re-read it twice. I’d spent years focused on neurological repair, growth factors, and cellular signaling —…
-
SS-31 Peptide Research: A Neurosurgeon’s Perspective on Mitochondrial Protection
The first time a colleague handed me a paper on SS-31 peptide, I almost set it aside. A mitochondria-targeting tetrapeptide felt like fringe science — not the hard clinical data I’d built my career on. Then I read the mechanism. A compound that specifically partitions into the inner mitochondrial membrane, binds cardiolipin, and reduces oxidative…